Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Many anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) neutralizing
antibodies target the angiotensin-converting enzyme 2 (ACE2) binding site on viral spike …

HIV-1 Env mediates viral entry into host cells and is the sole target for neutralizing
antibodies. However, Env structure and organization in its native virion context has eluded …

Multivalent presentation of viral glycoproteins can substantially increase the elicitation of
antigen-specific antibodies. To enable a new generation of anti-viral vaccines, we designed …

Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are
important leads for HIV vaccine design. Most V2-apex bnAbs engage Env with an …

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal
models, suggesting that a vaccine that elicits these antibodies would be protective in …

A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb)
response, yet vaccine-mediated induction of such a response in primates remains a …

HIV-1 Env, a trimer of gp120-gp41 heterodimers, mediates membrane fusion after binding
host receptor CD4. Receptor binding displaces V1V2 loops from Env's apex, allowing …

Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and
antibody coevolution. Previous studies showed that sequential immunization with a V3 …